A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of Two Concentrations of SBI-100 Ophthalmic Emulsion in Patients With Elevated Intraocular Pressure
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Tetrahydrocannabinol valine hemisuccinate (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Skye Bioscience
- 10 Jun 2024 According to a Skye Bioscience media release, the company to discontinue clinical development and spending related to SBI-100 OE and any R&D associated with SBI-100, including its ophthalmology pipeline, and direct all clinical development resources to its metabolic program.
- 10 Jun 2024 Results presented in the Skye Bioscience media release.
- 10 Jun 2024 Primary endpoint has not been met. (Ocular hypotensive efficacy, according to a Skye Bioscience media release.